Fox Run Management L.L.C. Acquires New Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Fox Run Management L.L.C. bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,769 shares of the company’s stock, valued at approximately $80,000.

Other large investors also recently bought and sold shares of the company. Point72 Asset Management L.P. boosted its position in shares of Olema Pharmaceuticals by 14.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 3,687,374 shares of the company’s stock worth $44,027,000 after buying an additional 475,447 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Olema Pharmaceuticals by 168.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock valued at $3,949,000 after purchasing an additional 207,565 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Olema Pharmaceuticals by 658.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company’s stock worth $2,162,000 after purchasing an additional 157,171 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Olema Pharmaceuticals by 10.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after purchasing an additional 97,428 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its position in shares of Olema Pharmaceuticals by 80.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 212,246 shares of the company’s stock worth $1,237,000 after purchasing an additional 94,651 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Down 2.1 %

Shares of NASDAQ:OLMA opened at $4.11 on Friday. The firm has a 50-day simple moving average of $4.98 and a 200 day simple moving average of $8.08. Olema Pharmaceuticals, Inc. has a fifty-two week low of $3.93 and a fifty-two week high of $16.62. The company has a market cap of $280.85 million, a PE ratio of -1.88 and a beta of 2.11.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.12. As a group, research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Oppenheimer reissued an “outperform” rating and set a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. Finally, JPMorgan Chase & Co. decreased their target price on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Friday.

Insider Transactions at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv acquired 300,000 shares of Olema Pharmaceuticals stock in a transaction dated Wednesday, January 8th. The stock was acquired at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the transaction, the insider now owns 7,800,000 shares in the company, valued at approximately $44,928,000. This represents a 4.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 19.40% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.